| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.2510 |
| P8608 | Fatcat ID | release_4gnqtcck2fhipf7l67q3x2p52i |
| P698 | PubMed publication ID | 19199318 |
| P5875 | ResearchGate publication ID | 23986817 |
| P50 | author | Silvia Soddu | Q28833493 |
| Armando Bartolazzi | Q53869136 | ||
| Cinzia Rinaldo | Q57307102 | ||
| Salvatore Sciacchitano | Q57565755 | ||
| Roberto Dominici | Q59286304 | ||
| Marco Volante | Q85849462 | ||
| P2093 | author name string | Alessandra Ulivieri | |
| Emidio Luciani | |||
| Luca Lavra | |||
| Francesco Frasca | |||
| P2860 | cites work | Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain | Q39575066 |
| P433 | issue | 1 | |
| P304 | page(s) | 66-75 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas | |
| P478 | volume | 218 |
| Q48338460 | Choroid plexus carcinoma in children: the Head Start experience |
| Q86502255 | Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules |
| Q38143707 | Current management of choroid plexus carcinomas. |
| Q33816239 | Diagnostic utility of galectin-3 in thyroid cancer. |
| Q21134996 | Galectin-3 and Beclin1/Atg6 genes in human cancers: using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers |
| Q35741579 | Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin |
| Q34477775 | Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells |
| Q48159180 | Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. |
| Q90751205 | MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin |
| Q91862384 | Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin |
| Q33610280 | Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q36070574 | Mutant p53: one name, many proteins |
| Q39387810 | New Insights in Thyroid Cancer and p53 Family Proteins. |
| Q34382553 | Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling |
| Q36050222 | Poorly differentiated thyroid carcinoma: an incubating entity. |
| Q37716533 | Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression |
| Q48112435 | Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp |
| Q33940788 | The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
Search more.